DUBLIN & ROME--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

都柏林和罗马——（商业新闻短讯）——CRISPR许可公司ERS基因组学有限公司（“ERS”）和药物发现领域的领导者IRBM今天宣布了一项非排他性CRISPR/Cas9许可协议。该协议允许IRBM访问ERS的CRISPR/Cas9专利组合。

IRBM is a drug discovery CRO with expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases, and neuroscience. The company has contributed to the discovery and development of four marketed therapeutics for HIV, HCV, ovarian cancer, and cutaneous T-cell lymphoma..

IRBM是一家药物发现首席风险官，拥有从目标验证和命中发现到临床前候选人提名等各种治疗领域的专业知识，包括肿瘤学，传染病和神经科学。该公司为HIV、HCV、卵巢癌和皮肤T细胞淋巴瘤的四种上市治疗药物的发现和开发做出了贡献。。

Carlo Toniatti, MD, PhD, CSO, IRBM, said: “We are committed to delivering high quality drugs by leveraging our broad range of expertise and capabilities across the entire preclinical drug discovery continuum. With the integration of CRISPR/Cas9 gene editing technology we are increasing our capability to identify and validate potential drug targets, to generate more predictive pre-clinical models and to elucidate the mechanisms of action of novel therapeutics.”.

IRBM医学博士、博士、CSO Carlo Toniatti说：“我们致力于通过在整个临床前药物发现连续体中利用我们广泛的专业知识和能力来提供高质量的药物。随着CRISPR/Cas9基因编辑技术的整合，我们正在提高我们识别和验证潜在药物靶标的能力，以产生更具预测性的临床前模型，并阐明新疗法的作用机制。”。

John E Milad, CEO, ERS Genomics, commented: “We are committed to supporting cutting-edge research and expanding the horizons of medical innovation by providing companies such as IRBM with the ability to take advantage of CRISPR/Cas9 technology. We look forward to seeing the innovative ways in which our gene editing technology will be utilised in various stages of drug discovery, providing candidates for a wide range of therapeutic areas.”.

ERS基因组学首席执行官John E Milad评论道：“我们致力于支持尖端研究，并通过为IRBM等公司提供利用CRISPR/Cas9技术的能力来扩大医学创新的视野。我们期待着看到我们的基因编辑技术将在药物发现的各个阶段被利用的创新方式，为广泛的治疗领域提供候选人。”。

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including eukaryotic and prokaryotic cells such as mammalian cells, bacteria, archaea, yeasts, algae, and insects.

ERS Genomics为有兴趣在其商业计划中使用CRISPR/Cas9技术的公司提供许可。ERS在全球拥有100多项专利，其产品组合涵盖了CRISPR/Cas9在所有细胞中的使用，包括真核细胞和原核细胞，如哺乳动物细胞，细菌，古细菌，酵母，藻类和昆虫。

ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide..

ERS Genomics通过Emmanuelle Charpentier的直接许可证授予这些专利，目前在全球拥有近150个许可证。。